Group 1: Hims & Hers Health Inc (HIMS) - HIMS shares increased by 17.5%, trading at $54.50, with a record peak of $56.71, marking a 438.7% year-over-year gain [2] - The company aired an advertisement during the Super Bowl and is preparing to release its fourth-quarter results on February 24 [2] - Historically, HIMS has experienced negative post-earnings reactions, with five out of the last eight sessions closing lower the day after earnings [2] Group 2: Novo Nordisk A/S (NVO) - NVO shares decreased by 3.1%, trading at $79.29, and have dropped 42.3% over the past nine months [3] - The company is nearing its 52-week low of $78.17, with five consecutive daily losses [3] - NVO has faced resistance at the $90 level since late December [3] Group 3: Viking Therapeutics Inc (VKTX) - VKTX shares fell by 2.1%, trading at $28.70, and are on track for their fifth loss in the last six sessions [4] - The stock recently hit its lowest level in 12 months, despite receiving an "outperform" rating from Scotiabank with a price target of $102 [4] - VKTX has a 58.3% deficit over the past nine months and has declined by 28.5% this year [4]

Nearly a year ago, Viking Therapeutics (VKTX 3.50%) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug.Viking Therapeutics' weight management candidate could produce blockbuster sales down the road, but this isn't enough to hold the attention of a stock market obsessed with artificial intelligence (AI). When the market closed on Feb. 5, shares of Viking Therapeutics were down about 65% from the peak they reached ...

Viking Therapeutics (VKTX) reported a fourth-quarter 2024 loss per share of 32 cents, wider than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 25 cents per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it is yet to generate revenues.More on VKTX’s Q4 EarningsResearch and development expenses surged 51% year over year to $31 m ...

The excitement surrounding Viking Therapeutics (VKTX 3.49%) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have been hoping that another, larger healthcare company would acquire it for its promising GLP-1 treatment, VK2735 -- but that doesn't appear to be happening.And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's rapidly declining valuation be a sign that ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO Conference Call Participants Ryan Deschner - Raymond James Mike Ulz - Morgan Stanley Asim Rana - Truist Securities Jay Olson - Oppenheimer Annabel Samimy - Stifel Mayank Mamtani - B. Riley Securities Biren Amin - Piper Sandler Hardik Parikh - JPMorgan Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Justin ...

Financial Performance - For the three months ended December 31, 2024, Viking reported a net loss of $35.4 million, or $0.32 per share, compared to a net loss of $24.6 million, or $0.25 per share, in the same period in 2023[25]. - For the year ended December 31, 2024, Viking reported a net loss of $110.0 million, or $1.01 per share, compared to a net loss of $85.9 million, or $0.91 per share, in 2023[28]. - Viking's total operating expenses for the year ended December 31, 2024, were $150.9 million, compared to $100.8 million in 2023, reflecting a 49.7% increase[36]. - General and administrative expenses rose to $15.3 million in Q4 2024 from $8.8 million in Q4 2023, driven by legal, patent services, and professional fees[24]. - General and administrative expenses for the year ended December 31, 2024, were $49.3 million, up 33% from $37.0 million in 2023[27]. - Research and development expenses increased to $31.0 million in Q4 2024 from $20.5 million in Q4 2023, primarily due to manufacturing and personnel costs[23]. - For the year ended December 31, 2024, research and development expenses were $101.6 million, an increase of 59% from $63.8 million in 2023[26]. - As of December 31, 2024, Viking held cash, cash equivalents, and short-term investments of $903 million, significantly up from $362 million as of December 31, 2023[29]. - The company's total assets as of December 31, 2024, were $908.3 million, compared to $368.5 million as of December 31, 2023[38]. Clinical Development - The Phase 2 VENTURE study of VK2735 for obesity achieved statistically significant mean body weight reductions of up to 14.7% from baseline and 13.1% relative to placebo[6]. - The company plans to initiate Phase 3 studies for VK2735 in obesity in Q2 2025[5]. - In the Phase 2b VOYAGE trial, VK2809 demonstrated a median relative reduction in liver fat content ranging from 38% to 55% after 12 weeks[13]. - VK2809-treated patients showed MASH resolution rates of 63% to 75% compared to 29% for placebo[14]. - The Phase 1b study of VK0214 in X-ALD resulted in a 38% reduction in plasma levels of a key biomarker relative to placebo[20]. - Viking is developing VK2735, a dual agonist for metabolic disorders, which has shown positive signs of clinical benefit in Phase 1 and Phase 2 trials[31]. - VK2809, a small molecule for lipid and metabolic disorders, achieved both primary and secondary endpoints in a Phase 2b study for NASH and fibrosis[32]. - The company is also developing VK0214 for the treatment of X-ALD, which demonstrated significant reductions in plasma levels of VLCFAs in a Phase 1b trial[32]. - Viking plans to file an IND application for its dual amylin and calcitonin receptor agonist program later this year[22]. - The company expects to report data from the VENTURE-Oral Dosing trial in 2H25, evaluating VK2735 as an oral tablet[12].

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway Strong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Viking Therapeutics, Inc. (VKTX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Viking Therapeutics curre ...

Viking Therapeutics (VKTX) is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 27 cents per share. Estimates for 2025 loss per share have improved slightly from $1.42 to $1.41 in the past 60 days.See the Zacks Earnings Calendar to stay ahead of market-making news. Image Source: Zacks Investment ResearchVKTX’s ...

Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025.The company will host a conference call to discuss fi ...